Together we exceed
EpimAb aims to commercialize its technology as broadly as possible and maximize the number of programs based on the platform. Therefore, we plan to grant licenses under our intellectual property to multiple parties. A patent application covering the FIT-Ig technology has been submitted and the corresponding PCT application has been published recently.
The FIT-Ig technology is easy to use and straightforward allowing experienced molecular biologists to generate FIT-Igs with their own proprietary monoclonal antibodies as a starting point without additional support or resources from EpimAb needed. The company is, however, open to discuss collaborative arrangements.
EpimAb is actively looking for partners, that:
- have a pair of monoclonal antibodies and desire to combine in the FIT-Ig format as part of a licensing/collaboration agreement
- plan to test a combination or multiple combinations of monoclonal antibodies in the FIT-Ig format and obtain a license
- desire to obtain a license to a FIT-Ig program already characterized by EpimAb
- wish to discuss any other partnering options around FIT-Ig